Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815160 · ClinicalTrials.gov registry record · Phase 1
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
A Phase 1 study of Small Cell Lung Cancer Recurrent, sponsored by Debiopharm International.
- Active
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 13
- Study locations
NCT05815160: Active Phase 1 study of Small Cell Lung Cancer Recurrent, sponsored by Debiopharm International.
NCT05815160 is a Phase 1 study of Small Cell Lung Cancer Recurrent that is active but no longer recruiting, run by Debiopharm International. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). The trial reports 13 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05815160, a Phase 1 study of Small Cell Lung Cancer Recurrent, is active but no longer recruiting, sponsored by Debiopharm International.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended dose and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the recommended dose when administered in combination with carboplatin and etoposide.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Debio 0123
Study Locations (13)
Other
- Hospital Universitario de A Coruna - A Coruña
- Hospital Universitario Vall d'Hebron - Barcelona
- Hospital Clinic Barcelona - Barcelona
- Institut Catala D'Oncologia - Badalona - Barcelona
- Clinica Universidad de Navarra - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC) - Madrid
- NEXT Oncology Madrid - Madrid
- Hospital Quironsalud Malaga - Málaga
- Clinica Universidad de Navarra - Pamplona
- Hospital Clinico Universitario de Valencia - Valencia
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT05815160 still lists
NCT05815160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Small Cell Lung Cancer Recurrent appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT05815160 lists 13 locations in 3 states (Other, Arkansas, New York).
Frequently Asked Questions
What is clinical trial NCT05815160 about?
NCT05815160 is a clinical study titled "Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy". The primary purpose of part 1 (dose escalation) of this study is to identify the recommended dose and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety a...
What is the current status of trial NCT05815160?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2023-05-02. Estimated completion is 2026-03.
What conditions does trial NCT05815160 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer Recurrent.
What interventions are being tested in trial NCT05815160?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Debio 0123 (DRUG).
Who is sponsoring clinical trial NCT05815160?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815160 being conducted?
This trial has 13 study locations across Arkansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05815160's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI